2018
Structural correlates of cognitive impairment in normal pressure hydrocephalus
Peterson KA, Mole TB, Keong NCH, DeVito EE, Savulich G, Pickard JD, Sahakian BJ. Structural correlates of cognitive impairment in normal pressure hydrocephalus. Acta Neurologica Scandinavica 2018, 139: 305-312. PMID: 30428124, PMCID: PMC6492129, DOI: 10.1111/ane.13052.Peer-Reviewed Original ResearchConceptsNormal pressure hydrocephalusNPH patientsNeuropsychiatric symptomsPressure hydrocephalusNeuropsychiatric measuresNeuropsychological testsStructure volumesStriatal volume lossDeep gray matter structuresMeasures of apathySubcortical deep gray matter structuresT1-weighted magnetic resonanceGray matter structuresNAcc volumeSmaller caudateNeuropsychiatric changesHealthy controlsPathological basisNPH groupCaudate nucleusNucleus accumbensCaudate volumePatientsSubcortical regionsCognitive impairment
2017
Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects
DeVito EE, Herman AI, Konkus NS, Zhang H, Sofuoglu M. Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects. Pharmacology Biochemistry And Behavior 2017, 159: 55-61. PMID: 28716656, PMCID: PMC5573182, DOI: 10.1016/j.pbb.2017.07.002.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAdultAffectAtomoxetine HydrochlorideAttentionCocaine-Related DisordersCognitionCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHemodynamicsHumansInhibition, PsychologicalMaleMemory, Short-TermMiddle AgedNeuropsychological TestsSex CharacteristicsConceptsCocaine use disorderMeasures of attentionAbstinent cocaine usersSubjective drug effectsHuman laboratory studiesResponse inhibitionCognitive enhancementAbstinent individualsCognitive enhancersBehavioral treatmentAddictive processClinical populationsAtomoxetineCognitive impairmentNorepinephrine transporter inhibitorUse disordersCocaine usersCardiovascular effectsMoodMedication effectsPoor clinical outcomeDose-dependent effectIndividualsDrug effectsMemory
2016
Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders
Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders. Journal Of Dual Diagnosis 2016, 12: 90-106. PMID: 26828702, PMCID: PMC4837011, DOI: 10.1080/15504263.2016.1146383.Peer-Reviewed Original ResearchConceptsStimulant use disorderTransdiagnostic treatment targetExecutive controlAutomatic processCognitive impairmentUse disordersAddictive behaviorsCognitive functionDual-process modelCognitive behavioral therapyMaintenance of addictionCertain cognitive impairmentsPoor treatment retentionTreatment targetsAttentional biasApproach biasCognitive rehabilitationResponse inhibitionCognitive enhancementSustained attentionBehavioral therapyBehavioral treatmentAnxiety disordersBehavioral approachRates of lifetime
2012
Cognitive enhancement as a treatment for drug addictions
Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology 2012, 64: 452-463. PMID: 22735770, PMCID: PMC3445733, DOI: 10.1016/j.neuropharm.2012.06.021.Peer-Reviewed Original ResearchConceptsCognitive enhancementBehavioral interventionsExecutive inhibitory controlCognitive impairmentDrug addictionSelective cognitive functionsCurrent illicit drug usersPoor treatment retentionCognitive enhancing agentsSignificant cognitive impairmentSpecific behavioral interventionsChronic drug useCognitive remediationInhibitory controlMarijuana addictionCognitive enhancersBehavioral treatmentCognitive functionDrug use behaviorsMultiple addictionsSubstance usersTreatment retentionInhibition functionFuture researchUse behaviors